cloudyn.png
Tuesday January 31st, 2023 7:15PM

FDA panel backs much-debated ALS drug in rare, 2nd review

By The Associated Press
Related Articles
  Contact Editor

WASHINGTON (AP) — A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group earlier this year.

The Food and Drug Administration advisers voted 7-2 that data from Amylyx Pharma warranted approval, despite hours of debate about the strength and reliability of the company’s lone study. The FDA is not required to follow the group's advice, but its positive recommendation suggests an approval is likely later this month.

The FDA has approved only two therapies for the disease, amyotrophic lateral sclerosis, or ALS, which destroys nerve cells needed for basic functions like walking, talking and swallowing.

ALS patients and their families have rallied behind Amylyx’s drug, launching an aggressive lobbying campaign and enlisting members of Congress to push the FDA to grant approval.

Despite a negative review published by FDA’s internal scientists ahead of the meeting, a majority of the outside panelists said Amylyx had presented enough evidence to suggest the drug is helping patients live longer. The same group of neurology experts narrowly voted against the drug in March, due to concerns about missing data and other issues in the company’s study.

“To deprive ALS patients of a drug that might work, it’s probably not something I would feel terribly comfortable with,” said Dr. Liana Apostolova of Indiana University’s School of Medicine, who voted for approval. “At the previous meeting it wasn’t that clear and it’s still questionable.”

Amylyx also appeared to benefit from an unusual exchange in which a company executive — at the FDA’s request — committed to pull the drug from the market if its benefits aren’t confirmed by a large, ongoing study.

“I’m somewhat assured that if an approval is issued it can be withdrawn in the future,” Apostolova noted.

Wednesday’s vote concluded a rare second meeting to review several new statistical analyses submitted by Amylyx in support of the treatment’s benefit in slowing disease and extending life.

The ALS drug review is being closely watched as an indicator of FDA’s flexibility in reviewing experimental medications for the terminally ill and its ability to withstand outside pressure.

Dr. Billy Dunn, FDA’s neurology review chief, opened the meeting by detailing the “concerns and limitations” with Amylyx’s data, while emphasizing the need for new treatment options.

“We are highly sensitive to the urgent need for the development of new treatments for ALS,” Dunn said.

Dunn also noted that a larger Amylyx study being conducted in the U.S. and Europe could provide “more definitive results” by 2024.

In a highly unusual move, Dunn suggested the agency might be more willing to approve the drug if Amylyx would commit to withdrawing its medication if the ongoing 600-patient trial fails to show a benefit. He then called on the company’s co-founders to publicly commit to that step, and Amylyx co-CEO Justin Klee said the company would voluntarily withdraw its drug in that scenario.

The FDA has the power to force companies to pull drugs from the market, though it’s generally faster if drugmakers voluntarily take that step. In cases where companies resist removal the regulatory process can drag on for years.

“I think the FDA — with all due respect — significantly understates the complexity and likelihood of their pulling the product from the market,” said Dr. Caleb Alexander of Johns Hopkins University, one of the two panelists who voted against the drug.

Amylyx conducted one small, mid-stage trial of its drug that showed some benefit in slowing the disease, but it was plagued by missing data and other problems, according to FDA reviewers.

“The final result — for a single study — is borderline and not very statistically persuasive,” FDA statistician Tristan Massie told panelists.

The Cambridge, Massachusetts, company says follow-up data gathered after the study concluded showed the drug extended life. Patients who continued taking the drug survived about 10 months longer than patients who never took the drug, according to a new company analysis.

Panelists favoring the drug cited that data, along with the drug’s mild side effects, to suggest there would be little downside for patients even if it doesn’t ultimately slow ALS.

“The drug is not harmful — it seems like it has a benefit — there’s no safety signal here,” said Dean Follmann, a biostatistician with the National Institutes of Health.

Earlier Wednesday, more than 20 ALS researchers, patients and family members told the advisers they supported approval. The agency has also received more than 1,200 written comments, largely from ALS patient advocates.

“I’m asking you to approve it because I know it works. It’s extending my life and I want that for others,” said Greg Canter, who was diagnosed with ALS in 2018 and participated in Amylyx's study. He credits the drug with improving his lung capacity and slowing his functional decline.

Amylyx’s medication comes as a powder that combines two older drugs: one prescription medication for liver disorders and a dietary supplement used in traditional Chinese medicine.

Hanging over the review is FDA’s controversial approval of the Alzheimer’s drug Aduhelm last year, which was reviewed by the same agency scientists and outside advisers.

In that case, the FDA disregarded the overwhelmingly negative vote by its outside advisers, three of whom resigned over the decision. The agency's approval — which followed irregular meetings with drugmaker Biogen — is under investigation by Congress and federal inspectors.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

  • Associated Categories: Associated Press (AP), AP National News, AP Online National News, Top General short headlines, AP Health, AP Business, AP Business - Corporate News, AP Business - Industries, AP Business - Health Care
© Copyright 2023 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
Record heat wave puts California in fossil fuel conundrum
A record heat wave put California in a fossil fuel conundrum: The state has had to rely more heavily on natural gas to produce electricity and avoid power outages while Democratic Gov. Gavin Newsom’s administration moves toward ending the use of oil and gas
6:39PM ( 19 minutes ago )
FDA panel backs much-debated ALS drug in rare, 2nd review
A panel of federal health advisers has voted to recommend approval for an experimental drug to treat Lou Gehrig’s disease
6:36PM ( 21 minutes ago )
Philippines ending compulsory mask wearing outdoors
Philippine officials say President Ferdinand Marcos Jr. has approved a recommendation to end the mandatory wearing of masks outdoors across the country more than two years after it was imposed at the height of the coronavirus pandemic
6:34PM ( 24 minutes ago )
Associated Press (AP)
Judge strikes down 1931 Michigan law criminalizing abortion
A judge has struck down Michigan’s 1931 anti-abortion law, months after suspending it
5:35PM ( 1 hour ago )
Trump-backed Diehl to take on Healey in Mass. governor race
A former state representative endorsed by former President Donald Trump, Geoff Diehl, has won the Republican nomination for Massachusetts governor over a businessman, Chris Doughty, who was considered the more moderate candidate in the race
5:28PM ( 1 hour ago )
EPA leader: Jackson needs 'fair share' of money to fix water
The head of the U.S. Environmental Protection Agency says he wants Mississippi’s capital city to receive “its fair share” of federal money to repair a troubled water system
5:27PM ( 1 hour ago )
AP National News
Heat wave puts California in fossil fuel conundrum
A record heat wave put California in a fossil fuel conundrum: The state has had to rely more heavily on natural gas to produce electricity and avoid power outages while Democratic Gov. Gavin Newsom’s administration moves toward ending the use of oil and gas
3:52PM ( 3 hours ago )
RBG's fashion collar highlights children's charity auction
A gold judicial collar made of glass beads that belonged to the late Justice Ruth Bader Ginsburg is being auctioned to benefit a charity
3:30PM ( 3 hours ago )
Obamas return to White House: Official portraits unveiled
Former President Barack Obama and former first lady Michelle Obama have unveiled their official White House portraits
2:59PM ( 3 hours ago )
AP Online National News
GOP gives thumbs down to Biden's $47B emergency request
President Joe Biden’s request for $47 billion in emergency funding is getting a thumbs down from Republicans in Congress
5:10PM ( 1 hour ago )
Jury awards $77M in suit against addiction treatment center
Nick Carusillo died when he was hit by multiple vehicles on a Georgia interstate, just days after he was abruptly discharged from an addiction treatment center
4:52PM ( 2 hours ago )
WHO: COVID cases drop everywhere, but pandemic not over
The World Health Organization says the number of new coronavirus cases fell everywhere in the world last week by about 12%
12:17PM ( 6 hours ago )
AP Health
Albania cuts diplomatic ties with Iran over July cyberattack
Albania's prime minister says the government has cut diplomatic ties with Iran and expelled the country’s embassy staff
4:00PM ( 2 hours ago )
Serena Williams' goodbye to U.S. Open a ratings boon to ESPN
It could have been just one night, but Serena Williams' exit from tennis turned into a boon for ESPN
3:26PM ( 3 hours ago )
Target drops mandatory CEO retirement age, Cornell to stay
Target is dropping the mandatory retirement age for its CEO, allowing its Chief Executive Brian Cornell to stay on for three more years
3:22PM ( 3 hours ago )
AP Business
Judge: Musk can use Twitter whistleblower but not delay case
Elon Musk will be able to include new evidence from a Twitter whistleblower as he fights to get out of his $44 billion deal to buy the social media company, but Musk won’t be able to delay a high-stakes October trial over the dispute, a judge ruled Wednesday
11:10AM ( 7 hours ago )
Apple puts on first in-person event since start of pandemic
Apple is expected to unveil the 14th series of its iconic and ubiquitous iPhone, its first in-person product launch event since before the coronavirus pandemic began
10:12AM ( 8 hours ago )
Navy wants new destroyer with lasers, hypersonic missiles
The Navy is getting ready to turn the chapter on its workhorse destroyer, the Arleigh Burke, which went into production more than 30 years ago
8:38AM ( 10 hours ago )
AP Business - Corporate News
EU wants price cap on Russian gas, energy companies to pay
European Commission President Ursula von der Leyen says European Union countries should set a price cap on Russian natural gas
12:10PM ( 6 hours ago )
UK leader Truss vows energy relief, rules out windfall tax
U.K.  Prime Minister Liz Truss has ruled out a windfall tax on oil companies to pay for her plans to tackle the energy crisis
12:04PM ( 6 hours ago )
Stock indexes push higher on Wall Street in midday trading
Stocks rose on Wall Street and erased weekly losses for major indexes as traders try to gauge whether the Federal Reserve will succeed in its mission to get inflation under control
11:48AM ( 7 hours ago )
AP Business - Industries
Biden touts legislative record as midterms approach
The news is filled with stories about investigations into former President Donald Trump and the fallout over the Supreme Court's ruling on abortion
5:20PM ( 1 day ago )
CVS Health moves closer to home care with $8B Signify deal
CVS Health will pay about $8 billion to expand into home care, a practice that could cut costs and keep patients happy, provided they get the help they need
3:32PM ( 1 day ago )
CVS to buy home health-care provider Signify for $8 billion
Drugstore operator CVS Health says it's buying home-healthcare provider Signify Health for $8 billion
7:57PM ( 1 day ago )
AP Business - Health Care
Record heat wave puts California in fossil fuel conundrum
A record heat wave put California in a fossil fuel conundrum: The state has had to rely more heavily on natural gas to produce electricity and avoid power outages while Democratic Gov. Gavin Newsom’s administration moves toward ending the use of oil and gas
6:39PM ( 19 minutes ago )
Philippines ending compulsory mask wearing outdoors
Philippine officials say President Ferdinand Marcos Jr. has approved a recommendation to end the mandatory wearing of masks outdoors across the country more than two years after it was imposed at the height of the coronavirus pandemic
6:34PM ( 24 minutes ago )
Monkeypox cases dropping, but racial disparities growing
The White House says it’s optimistic about a decline in monkeypox cases and an uptick in vaccinations against the infectious virus
6:25PM ( 32 minutes ago )
Canadian police arrest 2nd suspect in stabbing rampage
The Royal Canadian Mounted Police say the second suspect in the stabbing deaths of 10 people in the province of Saskatchewan has been located and is in police custody
6:22PM ( 36 minutes ago )
Ryan begins new chapter as Colts continue revolving QB story
Matt Ryan is eagerly waiting for the next chapter of his football career to begin
6:20PM ( 37 minutes ago )